{
    "clinical_study": {
        "@rank": "55147", 
        "arm_group": [
            {
                "arm_group_label": "Intramyocardial injection of BM cells", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Intramyocardial / intracoronary injection of BM cells", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "Intramyocardial, NOGA guided injection of bone marrow derived mononuclear cells in patients\n      with chronic ischemic heart disease and LVEF < 40%. The primary objective is to determine\n      whether the administration of the cells improves recovery of the left ventricular function.\n      Secondary objective is the finding of clinical or paraclinical parameters to predict\n      potential benefits of the treatment (basing on MRI characteristics such as size,\n      transmurality of the myocardial infarction and peri-lesional ischemia).\n\n      In the first part of the study 10 patients are treated without control group. This phase\n      serves as feasibility and safety part of the study."
        }, 
        "brief_title": "METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Ischemic Heart Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Heart Diseases", 
                "Ischemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic cardiac ischemic disease at least 4 months after one ore more myocardial\n             infarctions in a stable phase of the disease without option for revascularization\n\n          -  LVEF at echocardiography \u2264 40%\n\n          -  Significant regional LV wall motion dysfunction in the infarct related territory\n\n          -  Symptoms NYHA II-IV or CCS II-III (at least class III according to one of the two\n             classifications)\n\n          -  Patient agrees to comply with all follow-up evaluations\n\n          -  Age > 18 years old\n\n          -  Patient has been informed of the nature of the clinical trial and agrees to its\n             provision and has provided written informed consent\n\n        Exclusion Criteria:\n\n          -  Abnormal regional wall motion outside the infarct region\n\n          -  Need for revascularization in a non infarct-related coronary within 6 months\n\n          -  Patient has moderate to severe aortic valve disease, aortic or mitral prosthetic\n             valve\n\n          -  Patient has a significant mitral valve insufficiency (Effective Regurgitant office -\n             ERO - > 0.2 cm2 with possibility of mitral valve surgery\n\n          -  Left ventricular thrombus at echocardiography\n\n          -  LV-aneurysma planned surgical aneurysmectomy\n\n          -  LV-wall thickness < 5mm in the target territory\n\n          -  Congenital heart disorder of hemodynamic relevance\n\n          -  Known active infection or chronic infection with HIV, HBV or HCV\n\n          -  Chronic inflammatory disease\n\n          -  Serious concomitant disease with a life expectancy of less than one year\n\n          -  Follow up impossible (no fixed abode, etc)\n\n          -  Contraindication for cardiac MRI (i.e. pace maker, neurostimulator, claustrophobia)\n\n          -  Severe renal failure (creatinine > 250 mmol/l)\n\n          -  Relevant liver disease (GOT > 2x norm or spontaneous INR > 1,5)\n\n          -  Anemia (Hb < 8.5 mg/dl), Thrombocytopenia (< 100.000/\u00b5l)\n\n          -  Women of child bearing potential or pregnancy\n\n          -  Participation at a clinical trial in the last 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 27, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666132", 
            "org_study_id": "METHOD"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intramyocardial injection of BM cells", 
                "description": "only intramyocardial, NOGA guided injection on BM cells.", 
                "intervention_name": "intramyocardial injection of BM cells", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Intramyocardial / intracoronary injection of BM cells", 
                "description": "combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells", 
                "intervention_name": "intramyocardial / intracoronary injection of BM cells", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "control", 
                "description": "initially no intervention; crossover to therapy 6 months after enrollment", 
                "intervention_name": "Best medical therapy", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "LVEF < 40%", 
        "lastchanged_date": "August 15, 2012", 
        "location": {
            "contact": {
                "email": "daniel.suerder@cardiocentro.org", 
                "last_name": "Daniel Suerder, MD", 
                "phone": "+41 918053360"
            }, 
            "facility": {
                "address": {
                    "city": "Lugano", 
                    "country": "Switzerland", 
                    "zip": "6900"
                }, 
                "name": "Cardiocentro Ticino"
            }, 
            "investigator": {
                "last_name": "Tiziano Moccetti, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "3", 
        "official_title": "METHOD - Phase I/II Study of Intramyocardial Injection of Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease", 
        "overall_contact": {
            "email": "daniel.suerder@cardiocentro.org", 
            "last_name": "Daniel Suerder, MD", 
            "phone": "+41918053360"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Measurements of Troponine after cell injection", 
                "measure": "Troponin samples", 
                "safety_issue": "Yes", 
                "time_frame": "1 day after cell injection"
            }, 
            {
                "measure": "Number of patients with adverse events at short term", 
                "safety_issue": "Yes", 
                "time_frame": "within 1 week after cell injection"
            }, 
            {
                "measure": "Number of patients with adverse events at mid/long term", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 months after cell injection"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666132"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cardiocentro Ticino", 
            "investigator_full_name": "Daniel Suerder", 
            "investigator_title": "MD; senior attendant of Cardiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "First 10 patients + following randomization phase (n = 54); assessment of short term safety (1 week), Adverse events within 1 year; efficacy measurements 6 months after treatment", 
                "measure": "change in LVEF", 
                "safety_issue": "Yes", 
                "time_frame": "6 months vs. baseline"
            }, 
            {
                "measure": "change in Quality of life", 
                "safety_issue": "No", 
                "time_frame": "6 months vs. baseline"
            }, 
            {
                "description": "change in functional status (Vo2 max)", 
                "measure": "change in Vo2 max", 
                "safety_issue": "No", 
                "time_frame": "6 months vs. bl"
            }
        ], 
        "source": "Cardiocentro Ticino", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cardiocentro Ticino", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}